Literature DB >> 8396843

c-myc, ras p21 and p53 expression in pleomorphic adenoma and its malignant form of the human salivary glands.

H Deguchi1, H Hamano, Y Hayashi.   

Abstract

Using an immunohistochemical study and an immunoblot analysis, the expression of cellular oncogenes of the human salivary glands such as c-myc, ras p21, and p53 tumor-suppressor gene in pleomorphic adenomas and its malignant form, carcinoma in pleomorphic adenomas was examined to evaluate a differential biological significance, in comparison with that in normal salivary gland tissues. Immunohistochemically, the c-myc product was detected in 42% of the pleomorphic adenomas and in 56% of the carcinomas in pleomorphic adenoma. The ras p21 expression was observed in 24% of pleomorphic adenomas, and in 50% of carcinomas in pleomorphic adenoma. The p53 protein was detected in 18% of the pleomorphic adenomas and in 67% of the carcinomas in pleomorphic adenoma. Although there was no significant difference between the benign and malignant forms for the expression of c-myc, a statistical significance in ras p21 and p53 expression was found between the pleomorphic adenoma and its malignant form (P < 0.05) and P < 0.001, respectively). An immunoblotting assay clearly demonstrated the expression of c-myc and p53 gene products in both the benign and malignant forms of the pleomorphic adenoma, and that of ras p21 in the malignant form. These results indicate that activation of c-myc and ras p21 proto-oncogenes and the involvement of p53 mutation may play important roles in the malignant transformation of salivary gland pleomorphic adenoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396843     DOI: 10.1111/j.1440-1827.1993.tb01152.x

Source DB:  PubMed          Journal:  Acta Pathol Jpn        ISSN: 0001-6632


  9 in total

1.  Immunoexpression of c-erbB-2 and p53 in benign and malignant salivary neoplasms with myoepithelial differentiation.

Authors:  J C Rosa; A Félix; I Fonseca; J Soares
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

2.  Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours.

Authors:  N Kamio
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

3.  HRAS mutations in epithelial-myoepithelial carcinoma.

Authors:  Simion I Chiosea; Megan Miller; Raja R Seethala
Journal:  Head Neck Pathol       Date:  2013-11-26

4.  Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma.

Authors:  Bassel Tarakji; Omar Kujan; Mohammad Z Nassani
Journal:  J Cancer Epidemiol       Date:  2010-12-28

5.  Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.

Authors:  Jeong Won Kim; Gui Young Kwon; Jong-Lyel Roh; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim; Kyung-Ja Cho
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

6.  Astrocyte elevated gene-1 (AEG-1) is a marker for aggressive salivary gland carcinoma.

Authors:  Wen-Ting Liao; Ling Guo; Yi Zhong; Yan-Heng Wu; Jun Li; Li-Bing Song
Journal:  J Transl Med       Date:  2011-12-01       Impact factor: 5.531

7.  Malignant transformation of salivary gland pleomorphic adenoma: proof of principle.

Authors:  Matthijs H Valstar; Hetty Mast; Ivo Ten Hove; Laura R Moonen; Alfons Jm Balm; Ludi E Smeele; Senada Koljenović; Winand Nm Dinjens; Marie-Louise F van Velthuysen
Journal:  J Pathol Clin Res       Date:  2021-05-07

8.  Establishment and characterization of pleomorphic adenoma cell systems: an in-vitro demonstration of carcinomas arising secondarily from adenomas in the salivary gland.

Authors:  Satoshi Maruyama; Jun Cheng; Susumu Shingaki; Takashi Tamura; Shuichi Asakawa; Shinsei Minoshima; Yoshiko Shimizu; Nobuyoshi Shimizu; Takashi Saku
Journal:  BMC Cancer       Date:  2009-07-21       Impact factor: 4.430

9.  Canine mammary mixed tumours: a review.

Authors:  Geovanni Dantas Cassali; Angélica Cavalheiro Bertagnolli; Enio Ferreira; Karine Araújo Damasceno; Conrado de Oliveira Gamba; Cecília Bonolo de Campos
Journal:  Vet Med Int       Date:  2012-10-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.